This study found the HBV-ACLF patients had a significantly higher level of anti-HBc than CHB patients (4.95 ± 0.54 vs. 4.47 ± 0.84 log10 IU/mL), and the qAnti-HBc showed a comparable and complementary prognostic accuracy to MELD (model for end-stage liver disease) score in predicting clinical outcome (survival or death). This evidence concerns the gene KRT88P and End Stage Liver Disease.